Investigating a protein's role in fighting pneumonia caused by Gram-negative bacteria
Official title: The Function and Potential Application of Extracellular Vesicle Derived Clara Cell Protein 16 in Gram-negative Bacterial Pneumonia
Funded at University of Georgia · NIH-10905165 · Data updated 2026-11-12
This study is looking at how a protein called Clara Cell Protein 16 (CC16) might help treat hospital-acquired pneumonia caused by certain bacteria, with the goal of reducing inflammation and lung damage to improve recovery for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $501,482 |
| NIH project number | 1R56HL163607-01A1 |
| Project ID | NIH-10905165 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients who are hospitalized and at risk of developing pneumonia caused by Gram-negative bacteria.
✕Less likely to help
Patients with pneumonia caused by other types of bacteria or those who are not hospitalized may not benefit from this research.
What this research studies
This research focuses on understanding how Clara Cell Protein 16 (CC16) can help combat hospital-acquired pneumonia caused by Gram-negative bacteria. The study aims to explore the anti-inflammatory properties of CC16 and its potential as a therapeutic strategy to reduce inflammation and lung damage associated with this type of pneumonia. By examining the mechanisms of CC16 in lung tissues, researchers hope to identify new ways to improve patient outcomes and reduce the severity of infections. Patients may benefit from insights gained into how CC16 can be utilized in treatment protocols for pneumonia.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce the impact of hospital-acquired pneumonia on patients.
How similar studies have gone: Previous studies have shown promising results regarding the protective role of CC16 in various lung disorders, indicating potential for success in this novel application.
Where this research is happening
-
University of Georgia
Athens, United States Active
Researchers
- Principal investigator: Zhang, Duo — University of Georgia
- Study coordinator: Zhang, Duo
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Endothelial inflammation memory after sepsis and pneumonia
A scientist is studying how blood vessel cells “remember” sepsis and why survivors get worse when they catch pneumonia, with the goal of finding better ways to reduce organ damage.
-
Bacterial Biofilm Therapy with a Human Antibody to Help Antibiotics Work Better
A human antibody drug is being studied to disrupt bacterial biofilms and help standard antibiotics clear infections, especially around implants and catheters, in adults.
-
A tissue slice model to test treatments for Pneumocystis pneumonia in people with HIV/AIDS
Researchers are creating a lung-slice model to study Pneumocystis jirovecii pneumonia and test potential treatments using tissue from infected, immunosuppressed mice to better predict what might help people with HIV/AIDS.
-
Measuring respiratory and gut bacteria to predict pneumonia treatment failure
A project to understand how bacterial load in the lungs and gut changes during and after antibiotics for hospital-acquired and ventilator-associated pneumonia, with the goal of predicting which patients might fail treatment.
-
Better tests and treatments for Pneumocystis (PCP) pneumonia
Developing more accurate tests and safer treatment options for people with weakened immune systems who get Pneumocystis pneumonia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.